ភាគហ៊ុន Pfizer ធ្លាក់ចុះជាទិន្នន័យពីការខកចិត្តការសាកល្បងប្រឆាំងមេរោគ Covid

បានធ្វើបច្ចុប្បន្នភាពនៅម៉ោង 9:45 ព្រឹក EST

Pfizer  (ភីអេហ្វអេស) - ទទួលបានរបាយការណ៍របស់ Pfizer Inc shares moved lower Monday after the drugmaker posted disappointing late-stage data from a trial of its Covid antiviral treatment, Paxlovid, late Friday ahead of its first quarter earnings later this week.

Pfizer said a trial involving 3,000 adults with ‘household contacts’ that were infected by Covid failed to meet its primary endpoint of reducing the overall risk of infection to the person taking the drug. Patients that took a five-day course of Paxloivd were 32% less likely to be infected, Pfizer said, while those taking a ten-day course were 37% less likely.